Dose and outcomes in primary immunodeficiency disorders by Bonagura, V. R.
Journal Articles Donald and Barbara Zucker School of MedicineAcademic Works
2014
Dose and outcomes in primary immunodeficiency
disorders
V. R. Bonagura
Zucker School of Medicine at Hofstra/Northwell
Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons
This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.
Recommended Citation
Bonagura V. Dose and outcomes in primary immunodeficiency disorders. . 2014 Jan 01; 178():Article 2546 [ p.]. Available from:
https://academicworks.medicine.hofstra.edu/articles/2546. Free full text article.
Dose and outcomes in primary immunodeﬁciency disorders
V. R. Bonagura
Hofstra North Shore-LIJ School of Medicine,
Steven and Alexandra Cohen Children’s Medical
Center of New York, New York, NY, USA
Correspondence: V. R. Bonagura.
E-mail: vbonagura@nshs.edu
Currently, the principal form of treatment for patients with
primary immunodeficiency disorders (PID) in Europe
is subcutaneous immunoglobulin (SCIg) replacement
therapy. Conversely, until relatively recently, intravenous
immunoglobulin (IVIg) replacement was the preferred
option for treatment of PID in the United States. Patients
with PID are more susceptible to recurrent or severe infec-
tions than individuals without PID. A retrospective analysis
of data from the European Society of Immunodeficiencies
(ESID) registry, between 2004 and 2010, showed marked
regional variability in the clinical outcomes of patients with
PID receiving SCIg or IVIg replacement therapy [1]. In this
analysis, patients receiving IVIg appeared to present with
more serious bacterial infections and spend more days in
hospital than patients receiving SCIg. Furthermore, in a
subgroup of patients, those who switched from IVIg to SCIg
replacement therapy spent fewer days in hospital after the
switch [1].
However, there are a number of considerations when
deciding on the route of immunoglobulin G (IgG) adminis-
tration. The volume of immunoglobulin (Ig)G that can be
given into the subcutaneous (s.c.) space can be limited
when compared with the volume that can be delivered
intravenously (i.v.); thus, SCIg must be administered more
frequently than IVIg. SCIg treatment regimens include
weekly, bi-weekly or daily push doses that can be self-
administered. Typical regimens for the i.v. route of adminis-
tration are once every 3–4 weeks given at home or in a
clinic setting. In contrast to the cycle of peak and trough
serum IgG levels following IVIg infusion, SCIg regimens
produce minimal variation in trough serum IgG levels [2].
Systemic side effects are more common with IVIg than
SCIg, and infusion site reactions are more common with
SCIg, particularly during the early phase of s.c. IgG replace-
ment therapy [2,3]. An alternative method to facilitate
SCIg administration is a pre-infusion of recombinant
hyaluronidase followed by a monthly dose of s.c. IgG. This
method has been reported to have a low rate of systemic
side effects, similar to conventional SCIg [4].
The impact of home-based monthly IVIg and weekly
SCIg self-infusions on health-related quality of life
(HRQoL), treatment satisfaction and patient preference for
either IgG replacement venue has been investigated in
patients with PID treated previously with IVIg in the hospi-
tal or at home [5]. Patients who switched from hospital-
based IVIg to IVIg or SCIg self-infusions at home reported
significantly fewer limitations with work/daily activities, sig-
nificantly improved quality of life (e.g. feeling of more
energy, less tiredness and fatigue) and better general health.
While s.c. IgG were preferred over i.v. infusions by PID
patients, overall patient satisfaction and preference for IgG
replacement therapy was linked to home IgG therapy [5].
Specifically, the effect on improving the quality of life
(QoL) for PID patients was less striking in the switch from
home-based IVIg to SCIg self-infusions at home; home
therapy was the major factor in improving QoL [5].
Administration of IgG via the s.c. route is becoming
increasingly popular in the United States, and in a survey of
European and US clinical immunologists the majority of
respondents agreed that IgG administered s.c. is as effective
as IVIg therapy [6]. However, the question still remains as
to the optimal dosage regimen that provides the best clinical
outcome in preventing serious and/or recurrent infections
in patients with PID. Progressive increments in the dose of
IVIg produce linear increases in trough IgG levels, leading
to a 27% decline in the incidence of pneumonia with every
100 mg/dl increase in trough IgG up to at least 1000 mg/dl
[7]. Similarly, higher SCIg doses have been shown to also
correlate with higher serum IgG levels. However, although
higher IgG serum levels achieved by SCIg infusions corre-
lated with lower rates of non-serious infections, there
was no correlation between the SCIg dose administered
and the rate of infection in this study [8]. Nevertheless,
higher SCIg doses appeared to provide improvements in a
bs_bs_banner
Clinical and Experimental Immunology IMMUNODEFICIENCIES doi:10.1111/cei.12492
7© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 7–9
number of clinical outcomes, including fewer days in hospi-
tal, fewer days on antibiotics and a reduced annual rate of
infection [8].
Although targeting a serum/trough IgG level that raises
IgG levels above 500 mg/dl is a useful guide in beginning
IgG replacement therapy for patients with PID [7,8], in
healthy individuals there is a wide variation in serum IgG
levels well above this ‘targeted’ serum IgG level [9]. Further-
more, the level of serum IgG that protects patients with PID
against recurrent or serious infections is likely to vary
widely for each patient, as it does in healthy individuals [9].
The suggested goal of therapy should be to identify the
individual ‘biological’ serum IgG trough level required to
maintain a PID patient as infection-free as possible [10].
The ‘biological’ level can be obtained by charting a patient’s
serious or recurrent infections against their IgG levels over
time, and is a ‘moving target’ because it can be altered by
changes in clinical status, such as changes in body weight,
pregnancy or the development of co-morbid conditions,
such as renal [10] and gastrointestinal disease. The concept
of targeting an individual PID patient’s ‘biological’ IgG
level is supported by data obtained by a large cohort
of patients with common variable immunodeficiency
(CVID) or X-linked agammaglobulinaemia (XLA) who
were followed-up over a period of 22 years [11]. This study
clearly showed that there is a wide range of serum IgG levels
that were required to keep these PID patients as infection-
free as possible, and that only some PID patients need the
largest doses of IgG that have been shown to reduce the
development of pneumonias [7]. In addition, there was
variability in the amount of IgG required to keep CVID
versus XLA patients healthy, suggesting that the original IgG
repertoire present in CVID versus XLA patients may be
important in determining the IgG dose required to keep
these two different PID patient populations healthy. More-
over, the wide variation in the dose of IgG used to keep PID
patients healthy did not exceed the wide range of serum
levels found in healthy, age-appropriate individuals.
A 5-year prospective study identified subgroups of
patients with PID at high risk of infection [12]. CVID
patients had a high risk of pneumonia if they had low IgG
and IgA levels at diagnosis or an IgA level <7 mg/dl with
bronchiectasis. In XLA, the only co-morbidity risk factor
identified for pneumonia was the presence of bronchiectasis
[12]. Although this remains controversial, PID patients with
bronchiectasis appear to require higher doses of IgG to
achieve the same trough IgG level as those without this
disease [11]. Use of higher doses of IVIg that provides IgG
levels >500 mg/dl may be required to decrease the incidence
and progression of bronchiectasis in patients with XLA and
CVID [13]. In another 2-year prospective study, IgG trough
levels >600 mg/dl were shown to be better in controlling
bacterial infections and pulmonary complications in
patients with CVID [14]. In addition, doses of 800–
>1100 mg/dl have been shown to produce a slower decline
in age-associated pulmonary function tests in adults with
PID [15].
In conclusion, individualizing the IgG dose and route of
administration, together with identification of a given PID
patient’s ‘biological IgG level’, helps prevent severe and
recurrent infections. In addition, individualization of
therapy can improve adherence and improve the QoL of
PID patients by allowing each individual patient to choose
the IgG replacement venue that best suits their lifestyle.
Finally, the goal of IgG replacement therapy is to provide
sufficient amounts of IgG, by the i.v. or s.c. route, to mini-
mize serious and recurrent infection. This can be achieved
by identifying and then maintaining each PID patient’s
‘biological IgG level’ that can vary over time depending on
the development of co-morbid conditions.
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